MacroGenics Presents Phase 1 Data at ASCO Showing Signs of Clinical Benefit for Margetuximab in HER2 Expressing Tumors; Phase 2 Clinical Trial Underway to Evaluate Activity in Patients with Advanced Breast Cancer

MacroGenics Presents Phase 1 Data at ASCO Showing Signs of Clinical Benefit for Margetuximab in HER2 Expressing Tumors; Phase 2 Clinical Trial Underway to Evaluate Activity in Patients with Advanced Breast Cancer 79.6 KB

The release as fetched from its publisher. macrogenics.com ↗